• January 18 2026
  US drugmakers threaten to withhold products from Europe over prices

  Pharmaceutical companies seek to make up any lost revenue after striking deals with Donald Trump to lower costs in US

  4 hours ago

  
• January 17 2026
  The best books of the week

  Off the Scales — the impact of weight-loss jabs, from our bodies to the pharma sector

  Focusing on Novo Nordisk, Aimee Donnellan’s book ranges across R&D, patents, medical effects and the stigma attached to obesity

  
• January 16 2026
  InterviewDrug prices

  Trump’s demand for higher NHS drug costs would be ‘huge backwards step’, medicines watchdog says

  Jonathan Benger tells FT that health service payments should not rise for years to come

  
• January 14 2026
  EQT in talks to take over Oxford BioMedica

  Buyout of UK-listed group would be latest private equity deal for European public company

  
• January 14 2026
  Lex

  Vaccines are no longer immune to pharma’s market swings

  One of the appeals of the jab business — its dependability — is under threat

  Premium content

  
• January 11 2026
  Healthcare companies set for deals spree as drug patents expire

  A gathering of pharmaceutical executives comes as the sector has rebounded from uncertainty over Trump’s policies

  
• January 9 2026
  Due Diligence

  Can Glencore and Rio Tinto make it work this time?

  Plus, Merck is in talks for a cancer drugmaker and hedge funds spar over credit default swaps

  Premium content

  
• January 9 2026
  Merck in talks to buy cancer drugmaker Revolution Medicines for up to $32bn

  US company is attempting to acquire the maker of a new treatment for pancreatic cancer

  
• January 8 2026
  Drugs research

  Obesity drug users will regain weight two years after ending medication, review finds

  Experts say health authorities need plans to deal with people coming off medicines such as Ozempic and Wegovy

  
• January 7 2026
  GSK PLC

  GSK hails promising trial results for hepatitis B treatment

  Drug could provide a cure for condition that affects more than 250mn people

  
• January 6 2026
  Biotech

  Amgen swoops on UK cancer biotech in deal worth up to $840mn

  Dark Blue Therapeutics was spun out of an Oxford university incubator in 2022

  
• January 5 2026
  US politics & policy

  US reduces number of recommended vaccines for children

  Shots against diseases such as polio and chickenpox will only be suggested for those considered high risk

  
• January 5 2026
  Drug prices

  Novo Nordisk launches US price war over weight-loss pills

  Lowest doses of Wegovy in oral form will start at $149 a month for American users until April

  
• January 2 2026
  Biotech

  Prices for lab monkeys surge on China biotech boom

  More drugs entering middle or late-stage development drive up demand

  
• January 1 2026
  Companies

  Business trends, wild cards and companies to watch in 2026

  Where power, profits and pressure points are likely to lie across five key sectors

  
• December 28 2025
  Europe races to placate pharma as Trump turns up the pressure

  Tariff deals with the US have bought time but investment momentum is elsewhere

  
• December 27 2025
  Lex

  Weight-loss drugs come for Fluffy and Fido

  If semaglutide can shrink a human waistline, why not a canine or feline one?

  Premium content

  
• December 23 2025
  Novo Nordisk AS

  Novo Nordisk weight-loss drug wins US approval as a daily pill

  Shares in Danish company rise as drugmaker secures lead in oral obesity treatment

  
• December 19 2025
  Biotech

  The billionaire ex-Enron trader trying to upend US drug policy

  John Arnold parlayed windfall from natural gas bets into a foundation that is challenging medicine approvals

  
• December 18 2025
  Cannabis industry

  Marijuana stocks tumble as Trump reclassifies drug but fails to legalise it

  US president’s order would categorise cannabis as less dangerous and remove it from grouping with heroin and LSD

  
• December 15 2025
  Hikma Pharmaceuticals PLC

  Hikma chief steps down after profit forecast cuts and factory delays

  Drugmaker installs former boss Said Darwazah after Riad Mishlawi’s surprise exit

  
• December 13 2025
  FT Magazine

  Jailed for gene-editing, a notorious scientist is not done yet

  He Jiankui’s experiment with human embryos caused global outrage. Can he make an unlikely comeback?

  
• December 11 2025
  Eli Lilly & Co

  Eli Lilly shot helped patients lose 29% of body weight

  Trial results are a boost to US pharmaceutical company’s booming obesity business

  
• December 11 2025
  EU business regulation

  EU trims exclusivity window for new drugs

  Cheaper generics will be allowed on to market a year earlier to curb costs

  
• December 11 2025
  Zealand Pharma AS

  Biotech boss urges pharma to move on from ‘weight-loss Olympics’

  Zealand Pharma chief says next-generation obesity drugs will need to be longer lasting and better tolerated

  

Topics to follow